[1]
Ratnakumaran R(2018)Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Scandinavian Journal of Gastroenterology 53 700-707
[1]
Ratnakumaran R(2018)Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. Scandinavian Journal of Gastroenterology 53 700-707